Clinical trials: Breast Neoplasms, Male
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Cancer, Breast Cancer
The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia
This qualitative study seeks to explore the unmet needs of individuals who have recently undergone a cancer diagnosis and completed the acute phase of treatment.
- Conditions
- Cancer, Breast Cancer, Prostate Cancer, Thyroid Cancer
- Trial name
- Survivorship (NCT06236373)
- Testing
- Focus Groups or Interviews
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- University of Modena and Reggio Emilia
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Estrogen Receptor Negative, HER2/Neu Negative
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
This phase I clinical trial studies the side effects and the best dose of dinaciclib when given together with epirubicin hydrochloride (epirubicin) in patients with metastatic (cancer that has spread to other parts of the body)…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative
- Trial name
- NCT01624441
- Testing
- Dinaciclib, Epirubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Breast Cancer
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CYH33 in combination with olaprib in patients with DDR gene mutations and/or PIK3CA mutations, in patients who have progressed on prior…
- Conditions
- Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer
- Trial name
- NCT04586335
- Testing
- CYH33
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 24 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Breast Cancer
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00079118
- Testing
- docetaxel, irinotecan hydrochloride
- Where
- 162 sites in United States
- Volunteers
- 70 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Colorectal Cancer
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
This research study will test the efficacy of interactive, web-based interventions that improve diet, physical activity and weight management changes among early stage survivors of breast, prostate, colorectal, endometrial…
- Conditions
- Breast Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer
- Trial name
- AMPLIFY (NCT04000880)
- Testing
- Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health, Diet-Exercise, Exercise-Diet
- Where
- 2 sites in United States
- Volunteers
- 603 people
- Sponsor
- University of Alabama at Birmingham
Kidney Cancer, Head and Neck Cancer
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
The purpose of this study is to evaluate changes in tumor blood flow and disease response to the investigation agent, 177Lu-J591.
- Conditions
- Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT00967577
- Testing
- 177Lu-J591
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
Estrogen Receptor Negative, HER2/Neu Negative
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
This phase I trial studies the side effects and the best dose of veliparib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with ovarian cancer, fallopian tube cancer, or primary…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative
- Trial name
- NCT01145430
- Testing
- Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study
- Where
- 6 sites in United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer
The purpose of this study is to learn why certain drugs stop working in patients.In lab studies, tumors become resistant in several ways. Specific molecules seem to change and this may be why therapy stops working.
- Trial name
- NCT00897702
- Testing
- Blood draw, immunoenzyme technique, biopsy
- Where
- 7 sites in United States
- Volunteers
- 269 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Cancer
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.
- Trial name
- NCT04148937
- Testing
- LY3475070, Pembrolizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Vaginal Atrophy, Breast Cancer Female
Histological Modifications of Postmenopausal Vaginal Mucosa After Repeated Carbon Dioxide (CO2) Laser Treatment
To assess the long-term histological and clinical efficacy of MonaLisa Touch procedure for the management of the Genitourinary Syndrome of Menopause (GSM) in postmenopausal female patients.
- Conditions
- Vaginal Atrophy, Breast Cancer Female, Dyspareunia
- Trial name
- REPLAMOD (NCT04868812)
- Testing
- SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- IRCCS San Raffaele
Breast Cancer, Glioma
A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Brain, Lung, and Head and Neck Cancers
This study will examine, for the first time, the independent contribution of a patient's own genetic makeup to the development of post-radiation complications, permitting the future development of predictive tests to avoid…
- Conditions
- Breast Cancer, Glioma, Prostate Cancer, Carcinoma, Squamous Cell
- Trial name
- NCT00122239
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- AHS Cancer Control Alberta
Breast Cancer
Vaccine Therapy in Treating Patients With Breast Cancer
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells that express HER2/neu.
- Trial name
- NCT00524277
- Testing
- GP2 peptide + GM-CSF vaccine, GM-CSF (sargramostim), AE37 + GM-CSF vaccine
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 456 people
- Sponsor
- San Antonio Military Medical Center
Breast Cancer
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00019812
- Testing
- trastuzumab, paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Head and Neck Cancer, Urologic Cancer
In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients
The aim of this study is to describe the tumor microenvironment of solid tumors and to understand the changes induced by anti-cancer treatments, particularly those developed by Innate Pharma.
- Conditions
- Head and Neck Cancer, Urologic Cancer, Lung Cancer, Breast Cancer
- Trial name
- FUTURE (NCT06827639)
- Testing
- blood collection, tissue specimen collection
- Where
- France
- Volunteers
- 640 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy
This phase II trial studies how well carbon dioxide fractional (CO2RE) laser works in treating participants with stage 0-III hormone receptor-positive breast cancer with vulvovaginal atrophy associated with dryness, inflammation…
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT03666819
- Testing
- Carbon Dioxide Fractional Laser, Questionnaire Administration
- Sponsor
- Mayo Clinic
Bone Metastases From Breast or Prostate Cancer
18F-NaF PET Imaging for Bone Scintigraphy
The purpose of this study is to compare, in patients with prostate or breast cancer, the accuracy of 18F-NaF PET imaging to 99mTc whole body bone scans with single-photon emission computed tomography (SPECT).
- Trial name
- NCT01930812
- Testing
- NaF PET/CT Imaging, 99mTc-medronate whole body bone scan with SPECT, 18F-Sodium Fluoride (NaF)
- Where
- 10 sites in Canada
- Volunteers
- 286 people
- Sponsor
- British Columbia Cancer Agency
Ovarian Cancer, Breast Cancer
Comprehensive Outcomes for After Cancer Health
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer.
- Conditions
- Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
- Trial name
- COACH (NCT05349227)
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 7 sites in United States
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Pack Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.